Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.
Amyloidosis
Cardiac imaging
Heart failure
Laboratory markers
Monitoring tools
Transthyretin amyloid cardiomyopathy
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
21
04
2021
received:
23
12
2020
accepted:
23
04
2021
pubmed:
30
4
2021
medline:
11
8
2021
entrez:
29
4
2021
Statut:
ppublish
Résumé
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening condition with a heterogeneous clinical presentation. The recent availability of treatment for ATTR-CM has stimulated increased awareness of the disease and patient identification. Stratification of patients with ATTR-CM is critical for optimal management and treatment; however, monitoring disease progression is challenging and currently lacks best-practice guidance. In this report, experts with experience in treating amyloidosis and ATTR-CM developed consensus recommendations for monitoring the course of patients with ATTR-CM and proposed meaningful thresholds and frequency for specific parameters. A set of 11 measurable features across three separate domains were evaluated: (i) clinical and functional endpoints, (ii) biomarkers and laboratory markers, and (iii) imaging and electrocardiographic parameters. Experts recommended that one marker from each of the three domains provides the minimum requirements for assessing disease progression. Assessment of cardiac disease status should be part of a multiparametric evaluation in which progression, stability or improvement of other involved systems in transthyretin amyloidosis should also be considered. Additional data from placebo arms of clinical trials and future studies assessing ATTR-CM will help to elucidate, refine and define these and other measurements.
Identifiants
pubmed: 33915002
doi: 10.1002/ejhf.2198
pmc: PMC8239846
doi:
Substances chimiques
Prealbumin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
895-905Informations de copyright
© 2021 European Society of Cardiology.
Références
Eur Heart J. 2015 Oct 7;36(38):2585-94
pubmed: 26224076
ESC Heart Fail. 2018 Feb;5(1):27-35
pubmed: 28869340
JACC Cardiovasc Imaging. 2018 Dec;11(12):1924-1926
pubmed: 30121265
JACC Cardiovasc Imaging. 2015 Jan;8(1):50-59
pubmed: 25499132
JACC Cardiovasc Imaging. 2020 Jun;13(6):1314-1321
pubmed: 31864976
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
ESC Heart Fail. 2019 Feb;6(1):3-9
pubmed: 30311454
Circulation. 2019 Jan 22;139(4):431-443
pubmed: 30586695
JACC Cardiovasc Imaging. 2020 Jun;13(6):1337-1347
pubmed: 32417330
J Nucl Med. 2021 May 10;62(5):716-722
pubmed: 32887756
Neth Heart J. 2019 Nov;27(11):525-536
pubmed: 31359320
Circ Heart Fail. 2019 Jun;12(6):e005407
pubmed: 31170802
Circulation. 2019 Aug 20;140(8):e333-e381
pubmed: 30586771
Ann Med. 2015;47(8):625-38
pubmed: 26611723
JACC CardioOncol. 2020 Sep;2(3):414-424
pubmed: 33073249
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1652-62
pubmed: 24841414
Curr Heart Fail Rep. 2020 Jun;17(3):77-83
pubmed: 32356182
Amyloid. 2020 Dec;27(4):266-274
pubmed: 32722948
Heart. 2007 Apr;93(4):476-82
pubmed: 17005715
Eur Heart J. 2017 Jun 21;38(24):1895-1904
pubmed: 28329248
Ann Noninvasive Electrocardiol. 2013 Mar;18(2):157-62
pubmed: 23530486
Circ Heart Fail. 2020 Feb;13(2):e006541
pubmed: 32065760
Circ Cardiovasc Imaging. 2015 Aug;8(8):
pubmed: 26259579
Circulation. 2012 Sep 4;126(10):1286-300
pubmed: 22949539
Eur Heart J. 2013 Aug;34(29):2281-329
pubmed: 23801822
J Card Fail. 2019 Nov;25(11):854-865
pubmed: 31473267
J Am Coll Cardiol. 2017 Jul 25;70(4):466-477
pubmed: 28728692
Amyloid. 2019 Sep;26(3):103-111
pubmed: 31339362
Eur Heart J. 2016 Jun 14;37(23):1826-34
pubmed: 26537620
J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891
pubmed: 31171094
JACC Cardiovasc Imaging. 2020 Jun;13(6):1353-1363
pubmed: 32498921
JACC Heart Fail. 2019 Aug;7(8):709-716
pubmed: 31302046
Scand J Clin Lab Invest. 2016 Oct;76(6):460-4
pubmed: 27347749
J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390
pubmed: 33183512
Circ Cardiovasc Imaging. 2017 Mar;10(3):e005588
pubmed: 28298286
Am J Clin Pathol. 2010 Sep;134(3):516-7; author reply 517
pubmed: 20716809
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Circulation. 1981 Dec;64(6):1227-34
pubmed: 7296795
ESC Heart Fail. 2020 Sep 13;:
pubmed: 32924285
Circulation. 2015 Oct 20;132(16):1570-9
pubmed: 26362631
Circulation. 2017 Apr 4;135(14):1357-1377
pubmed: 28373528
Intern Med. 2010;49(2):139-44
pubmed: 20075578
Amyloid. 2020 Sep;27(3):174-183
pubmed: 32482106
Arq Bras Cardiol. 2017 Jan;108(1):21-30
pubmed: 27992035
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
Circulation. 2019 Jul 2;140(1):16-26
pubmed: 31109193
Circulation. 2018 Feb 27;137(9):961-972
pubmed: 29483172
Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):470-8
pubmed: 21069320
Clin Biochem. 2015 Aug;48(12):807-10
pubmed: 25977070
Circulation. 2009 Sep 29;120(13):1203-12
pubmed: 19752327
Eur J Heart Fail. 2009 Jul;11(7):653-8
pubmed: 19502379
J Cardiovasc Magn Reson. 2018 Jan 03;20(1):2
pubmed: 29298704
J Nucl Cardiol. 2014 Apr;21(2):271-83
pubmed: 24347127
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
J Card Fail. 2018 Aug;24(8):504-511
pubmed: 30010028
Biochim Biophys Acta. 2013 Dec;1832(12):2442-50
pubmed: 23313577
J Am Heart Assoc. 2019 Dec 3;8(23):e014240
pubmed: 31771438
Eur J Heart Fail. 2014 Dec;16(12):1362-71
pubmed: 25371147
Heart. 2007 Aug;93(8):899-900
pubmed: 17639105
Heart. 2012 Oct;98(19):1436-41
pubmed: 22936681
Congest Heart Fail. 2010 Sep-Oct;16(5):208-13
pubmed: 20887617
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471